US20170022172A1 - Process for the synthesis of chlorzoxazone - Google Patents

Process for the synthesis of chlorzoxazone Download PDF

Info

Publication number
US20170022172A1
US20170022172A1 US15/214,499 US201615214499A US2017022172A1 US 20170022172 A1 US20170022172 A1 US 20170022172A1 US 201615214499 A US201615214499 A US 201615214499A US 2017022172 A1 US2017022172 A1 US 2017022172A1
Authority
US
United States
Prior art keywords
chlorzoxazone
chloro
aminophenol
process according
ethyl chloroformate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US15/214,499
Other versions
US9567308B1 (en
Inventor
Luigi BOGOGNA
Lavinia Cicione
Alessandro BAROZZA
Jacopo Roletto
Paolo Paissoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procos SpA
Original Assignee
Procos SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procos SpA filed Critical Procos SpA
Assigned to PROCOS S.P.A. reassignment PROCOS S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Barozza, Alessandro, BOGOGNA, LUIGI, CICIONE, Lavinia, PAISSONI, PAOLO, ROLETTO, JACOPO
Publication of US20170022172A1 publication Critical patent/US20170022172A1/en
Application granted granted Critical
Publication of US9567308B1 publication Critical patent/US9567308B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Definitions

  • Chlorzoxazone 5-chlorobenzo[d]oxazol-2(3H)-one, is a muscle relaxant which acts at central level and is used in the treatment of muscle spasms and the resulting pain. Chlorzoxazone acts on the spinal cord, by depressing/suppressing the reflexes.
  • chlorzoxazone (1) is synthesised by loading concentrated HCl, 4-chloro-2-aminophenol and urea into an autoclave and heating them in an inert atmosphere at 125° C. After cooling to room temperature, the crystalline paste that precipitates is suspended in 1500 parts of water, the pH of the suspension is adjusted to 5-6, and the paste is heated at 100° C. for an hour. After cooling, the residue is filtered and washed under vacuum to obtain chlorzoxazone (1) with a yield of 91%.
  • CN1560040 and CN103360336 also report the synthesis of chlorzoxazone (1) by reacting 4-chloro-2-aminophenol with urea at high temperatures in the presence of mineral acids (HCl or H 2 SO 4 ).
  • CN1560040 also discloses the synthesis of chlorzoxazone using phosgene
  • Another synthesis method involves cyclisation of 5-chloro-salicylamide by the action of 13% NaOH.
  • JP4834875 An alternative synthesis method not requiring the use of urea or phosgene is described in JP4834875, wherein a mixture of 4-chloro-2-nitrophenol, benzene, RhCl 3 and V 2 O 5 is heated in an autoclave with CO.
  • chlorzoxazone (1) is obtained by heating a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
  • a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
  • a base e.g. triethylamine
  • SK278412 describes a process wherein 4-chloro-2-nitrophenol is carbonylated with CO at high temperatures in the presence of catalytic systems such as S, COS, H 2 S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V 2 O 5 , V 2 S 5 , NH 3 VO 3 ).
  • catalytic systems such as S, COS, H 2 S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V 2 O 5 , V 2 S 5 , NH 3 VO 3 ).
  • EP0087347 discloses (Example 7) the synthesis of chlorzoxazone (1) obtained directly from the nitro derivative in the presence of pyridine and of a catalyst based on palladium and molybdenum in a CO atmosphere (200 bars) at 200° C. Cyclic carbamate is then isolated by cooling, filtration of the catalyst and recrystallisation of the product from water.
  • RO75779 discloses the synthesis of chlorzoxazone (1) from 5-Cl-salicylamide; in particular, the desired product is obtained by treating the amide in water, NaOH and butanol with 13% NaOCl at 35° C.
  • the process takes place by degrees, without isolation of intermediate reaction products.
  • the process therefore comprises:
  • the process of the invention typically involves the synthesis of chlorzoxazone (1) by acylation of 4-chloro-2-aminophenol with ethyl chloroformate in an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
  • an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
  • Chlorzoxazone (1) obtained is isolated directly from the reaction mixture by simple filtration. The quality of the synthesised product exceeds 98%.
  • the process is performed as follows:
  • 1 mole of 4-chloro-2-aminophenol is reacted with 0.9-1.5 moles of ethyl chloroformate, preferably 1.2-1.4 moles, in the presence of an inorganic base, preferably potassium carbonate, in quantities ranging from 1.0 to 4.0 moles, preferably from 2.0 to 3.0 mole equivalents.
  • the reaction is performed in organic solvent or mixtures of solvents selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate or in water, preferably in ethyl acetate, acetonitrile, N,N-dimethylformamide and water, in the temperature range between 0° C.
  • reaction temperature addition temperature
  • 80° C. or reflux temperature in the case of low-boiling solvents, preferably at the temperature of 55-60° C. 4-15 volumes of solvent are used, preferably 5-7 volumes relative to the quantity of 4-chloro-2-aminophenol.
  • the reaction is monitored by UPLC analysis using an ACQUITY UPLC® BEH C18 column, 17 ⁇ m, 2.1 ⁇ 50 mm, and water/acetonitrile/0.1% formic acid as eluent phase.
  • the reaction mixture containing chlorzoxazone (1) is cooled to the temperature of 0-25° C., preferably 0-10° C., and filtered.
  • the solid is re-washed with water and dried under vacuum at the temperature of 30-90° C., preferably 60-70° C., to obtain chlorzoxazone with a purity exceeding 98%.
  • the resulting solid can be further purified if necessary by recrystallisation from ethyl acetate, ethanol or other known solvents.
  • the process of the invention is particularly advantageous in that ethyl chloroformate is cheap and readily available, is not classified as a toxic gas, unlike phosgene and CO, does not need strict anhydrous conditions, which means that the reaction can take place in water, and does not need high reaction temperatures as with the use of urea.
  • chlorzoxazone (1) is obtained directly from the reaction mixture by simple filtration of the suspension at the end of the reaction with very high yields and quality, thus considerably simplifying the work-up stages described in the literature.
  • Ethyl chloroformate (9.8 g, 90.5 mmol) is dripped into a suspension of potassium carbonate (27.9 g, 201.8 mol) and 4-chloro-2-aminophenol (10.0 g, 69.6 mmol) in ethyl acetate (70 mL), heated to 60° C., in 4 hours. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with ethyl acetate (15 mL).
  • Ethyl chloroformate (2.9 g, 26.3 mmol) is dripped into a solution of 4-chloro-2-aminophenol (3.0 g, 20.9 mmol) and triethylamine (2.7 g, 26.3 mmol) in acetonitrile (20.9 mL), cooled to 0° C. The mixture is left under stirring at 0° C. for one hour, and potassium carbonate (8.4 g, 60.8 mmol) is then added. The resulting mixture is left under stirring at 60° C. for 18 h. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with acetonitrile (5 mL).
  • Ethyl chloroformate (1.96 g, 18.1 mmol) is dripped into a suspension of sodium bicarbonate (5.8 g, 69.0 mmol) and 4-chloro-2-aminophenol (2.0 g, 13.9 mmol) in water (11 ml) at 0° C.
  • the mixture is left to stand at room temperature for about half an hour, after which potassium carbonate is added and the reaction mixture is heated to 55-60° C.
  • the reaction is finished after 2 hours.
  • the reaction mixture is filtered and re-washed with water (10 mL) to obtain chlorzoxazone (1) (2.3 g, 13.6 mol) with a purity exceeding 95%.
  • Molar yield from 4-chloro-2-aminophenol to chlorzoxazone 98%.

Abstract

Disclosed is a process for the synthesis of chlorzoxazone (1) from 4-chloro-2-aminophenol and ethyl chloroformate in the presence of a base.
Figure US20170022172A1-20170126-C00001
The process is particularly advantageous because it uses ethyl chloroformate instead of triphosgene, a highly dangerous reagent that releases phosgene and must be handled with extremely strict procedures to guarantee the safety of operators in industrial facilities.
Ethyl chloroformate allows the possibility of working with a number of solvents, including water.
The yield and purity of the product obtained are very high.

Description

  • This application claims priority to and the benefit of Italian Patent Application No. 102015000037594 filed on Jul. 23, 2015, incorporated herein by reference in its entirety.
  • BACKGROUND OF THE INVENTION
  • Chlorzoxazone, 5-chlorobenzo[d]oxazol-2(3H)-one, is a muscle relaxant which acts at central level and is used in the treatment of muscle spasms and the resulting pain. Chlorzoxazone acts on the spinal cord, by depressing/suppressing the reflexes.
  • A number of examples of synthesis of chlorzoxazone (1) from 4-chloro-2-aminophenol, into which an acyl group, usually from urea or phosgene, is inserted, are described in the literature. Cases in which the carbonyl group inserted is directly gaseous CO are also reported.
  • A representative example of the use of urea for the synthesis of chlorzoxazone (1) is reported in U.S. Pat. No. 3,812,138 (DE2131366), which discloses the formation of dibenzothiazolones from various aminophenols/aminothiols in the presence of urea and mineral acids according to the following synthesis scheme:
  • Figure US20170022172A1-20170126-C00002
  • Specifically, chlorzoxazone (1) is synthesised by loading concentrated HCl, 4-chloro-2-aminophenol and urea into an autoclave and heating them in an inert atmosphere at 125° C. After cooling to room temperature, the crystalline paste that precipitates is suspended in 1500 parts of water, the pH of the suspension is adjusted to 5-6, and the paste is heated at 100° C. for an hour. After cooling, the residue is filtered and washed under vacuum to obtain chlorzoxazone (1) with a yield of 91%.
  • The patent does not report the degree of purity of the product obtained and, despite the high yield of the process, this synthesis is not particularly economical in terms of energy because very high temperatures are used. Moreover, the required work-up considerably increases the volumes of work, making it inefficient on an industrial scale.
  • CN1560040 and CN103360336 also report the synthesis of chlorzoxazone (1) by reacting 4-chloro-2-aminophenol with urea at high temperatures in the presence of mineral acids (HCl or H2SO4).
  • CN1560040 also discloses the synthesis of chlorzoxazone using phosgene
  • Figure US20170022172A1-20170126-C00003
  • The same document also describes the synthesis of chlorzoxazone (1) from the nitro derivative by reacting it with gaseous CO, which leads to the formation of cyclic carbamate
  • Figure US20170022172A1-20170126-C00004
  • Another synthesis method involves cyclisation of 5-chloro-salicylamide by the action of 13% NaOH.
  • Figure US20170022172A1-20170126-C00005
  • An alternative process using phosgene is reported in U.S. Pat. No. 3,369,022. The cyclisation of 4-chloro-2-aminophenol is described in procedure no. 2, according to the following synthesis scheme:
  • Figure US20170022172A1-20170126-C00006
  • In particular, a solution of phosgene in ethyl acetate is dripped into a suspension of 4-chloro-2-aminophenol and sodium acetate in ethyl acetate. The reaction mixture is heated to reflux and cooled, then washed with water containing 5% hydrochloric acid. After a distillation under vacuum and a further crystallisation, the product is obtained.
  • The procedure does not provide any data relating to the yield or purity of the chlorzoxazone (1) obtained, but even if they were excellent, the process presents the significant drawback of the manageability of phosgene, a particularly reactive, toxic reagent which requires special precautions for both use and disposal.
  • Another example of synthesis of chlorzoxazone (1) involving the use of phosgene is reported in EP0477819. The procedure described therein also appears unsatisfactory in terms of yields.
  • Alternative methods of synthesising chlorzoxazone are described in U.S. Pat. No. 2,895,877. Starting with 2-amino-5-chlorobenzoxazole or N-(5-chloro-2-hydroxyphenyl)urea at reflux in 1N HCl a solid precipitates which, after a basic work-up and an acid work-up, is crystallised from a suitable solvent.
  • An alternative synthesis method not requiring the use of urea or phosgene is described in JP4834875, wherein a mixture of 4-chloro-2-nitrophenol, benzene, RhCl3 and V2O5 is heated in an autoclave with CO.
  • Figure US20170022172A1-20170126-C00007
  • Also in JP58225072, chlorzoxazone (1) is obtained by heating a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
  • SK278412 describes a process wherein 4-chloro-2-nitrophenol is carbonylated with CO at high temperatures in the presence of catalytic systems such as S, COS, H2S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V2O5, V2S5, NH3VO3).
  • EP0087347 discloses (Example 7) the synthesis of chlorzoxazone (1) obtained directly from the nitro derivative in the presence of pyridine and of a catalyst based on palladium and molybdenum in a CO atmosphere (200 bars) at 200° C. Cyclic carbamate is then isolated by cooling, filtration of the catalyst and recrystallisation of the product from water.
  • The use of CO is problematic; said gas is highly poisonous, and insidious because it is odourless, colourless and tasteless. Its extremely hazardous nature requires particular precautions which make its industrial use extremely complicated.
  • RO75779 discloses the synthesis of chlorzoxazone (1) from 5-Cl-salicylamide; in particular, the desired product is obtained by treating the amide in water, NaOH and butanol with 13% NaOCl at 35° C.
  • Figure US20170022172A1-20170126-C00008
  • On the basis of the information set out above, there is clearly a need to find a process for synthesising chlorzoxazone (1) that is easier to manage industrially, safer, by avoiding the use of reagents which are extremely hazardous to humans and the environment, and more economical.
  • DESCRIPTION OF THE INVENTION
  • An advantageous process for the preparation of chlorzoxazone (1) has been found wherein 4-chloro-2-aminophenol is surprisingly closed with cyclic urethane due to ethyl chloroformate in the presence of a base, according to the following scheme:
  • Figure US20170022172A1-20170126-C00009
  • The process takes place by degrees, without isolation of intermediate reaction products.
  • The process therefore comprises:
  • 1) acylation of 4-chloro-2-aminophenol (cyclisation of the various acylation products);
  • 2) isolation of chlorzoxazone (1) from the reaction mixture by simple filtration of the reaction solvent.
  • The process of the invention typically involves the synthesis of chlorzoxazone (1) by acylation of 4-chloro-2-aminophenol with ethyl chloroformate in an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
  • The order in which the various solvents, raw materials and base are added can differ from that reported below.
  • Chlorzoxazone (1) obtained is isolated directly from the reaction mixture by simple filtration. The quality of the synthesised product exceeds 98%.
  • According to a preferred embodiment of the invention, the process is performed as follows:
  • 1 mole of 4-chloro-2-aminophenol is reacted with 0.9-1.5 moles of ethyl chloroformate, preferably 1.2-1.4 moles, in the presence of an inorganic base, preferably potassium carbonate, in quantities ranging from 1.0 to 4.0 moles, preferably from 2.0 to 3.0 mole equivalents. The reaction is performed in organic solvent or mixtures of solvents selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate or in water, preferably in ethyl acetate, acetonitrile, N,N-dimethylformamide and water, in the temperature range between 0° C. (addition temperature) and 80° C. or reflux temperature in the case of low-boiling solvents, preferably at the temperature of 55-60° C. 4-15 volumes of solvent are used, preferably 5-7 volumes relative to the quantity of 4-chloro-2-aminophenol. The reaction is monitored by UPLC analysis using an ACQUITY UPLC® BEH C18 column, 17 μm, 2.1×50 mm, and water/acetonitrile/0.1% formic acid as eluent phase. After completion of the reaction, the reaction mixture containing chlorzoxazone (1) is cooled to the temperature of 0-25° C., preferably 0-10° C., and filtered. The solid is re-washed with water and dried under vacuum at the temperature of 30-90° C., preferably 60-70° C., to obtain chlorzoxazone with a purity exceeding 98%. The resulting solid can be further purified if necessary by recrystallisation from ethyl acetate, ethanol or other known solvents.
  • The process of the invention is particularly advantageous in that ethyl chloroformate is cheap and readily available, is not classified as a toxic gas, unlike phosgene and CO, does not need strict anhydrous conditions, which means that the reaction can take place in water, and does not need high reaction temperatures as with the use of urea.
  • Moreover, chlorzoxazone (1) is obtained directly from the reaction mixture by simple filtration of the suspension at the end of the reaction with very high yields and quality, thus considerably simplifying the work-up stages described in the literature.
  • The invention is illustrated in detail in the following examples.
  • Example 1
  • Ethyl chloroformate (9.8 g, 90.5 mmol) is dripped into a suspension of potassium carbonate (27.9 g, 201.8 mol) and 4-chloro-2-aminophenol (10.0 g, 69.6 mmol) in ethyl acetate (70 mL), heated to 60° C., in 4 hours. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with ethyl acetate (15 mL). The crude product is reduced to a pulp in water for 1.5 hours, filtered under vacuum and washed with water (10 mL); chlorzoxazone (1) (11.1 g), with a purity exceeding 98%, is obtained. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 94%.
  • Example 2
  • Ethyl chloroformate (2.9 g, 26.3 mmol) is dripped into a solution of 4-chloro-2-aminophenol (3.0 g, 20.9 mmol) and triethylamine (2.7 g, 26.3 mmol) in acetonitrile (20.9 mL), cooled to 0° C. The mixture is left under stirring at 0° C. for one hour, and potassium carbonate (8.4 g, 60.8 mmol) is then added. The resulting mixture is left under stirring at 60° C. for 18 h. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with acetonitrile (5 mL). The crude product is reduced to a pulp in water for 1.5 hours, filtered under vacuum and washed with water (10 mL); chlorzoxazone (1), with a purity exceeding 96%, is obtained. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 92%.
  • Example 3
  • Ethyl chloroformate (1.96 g, 18.1 mmol) is dripped into a suspension of sodium bicarbonate (5.8 g, 69.0 mmol) and 4-chloro-2-aminophenol (2.0 g, 13.9 mmol) in water (11 ml) at 0° C. The mixture is left to stand at room temperature for about half an hour, after which potassium carbonate is added and the reaction mixture is heated to 55-60° C. The reaction is finished after 2 hours. The reaction mixture is filtered and re-washed with water (10 mL) to obtain chlorzoxazone (1) (2.3 g, 13.6 mol) with a purity exceeding 95%. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 98%.
  • UPLC-MS [M-H]=168 m/z
  • 1H-NMR (in DMSO) (chemical shifts expressed in ppm relative to the TMS signal): 11.82 (1H, s), 7.31 (1H, d), 7.15 (1H, dd), 7.13-7.11 (1H, m). 13C-NMR: 154.7, 142.6, 132.2, 128.2, 121.9, 111.2, 110.3.

Claims (9)

1. A process for the preparation of chlorzoxazone (1) wherein 4-chloro-2-aminophenol is reacted with ethyl chloroformate in the presence of a solvent and a base, according to the following scheme:
Figure US20170022172A1-20170126-C00010
2. A process according to claim 1 wherein the solvent is selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone, ethyl acetate or water.
3. A process according to claim 1 wherein the base is selected from potassium carbonate, potassium bicarbonate, sodium carbonate and sodium bicarbonate.
4. A process according to claim 1 wherein the molar ratio of 4-chloro-2-aminophenol to ethyl chloroformate ranges from 0.9 to 1.5
5. A process according to claim 1 wherein the reaction is carried out at a temperature ranging from 0° C. to 80° C. or the reflux temperature in the case of low-boiling solvents.
6. A process according to claim 1, wherein the solvent is selected from ethyl acetate, acetonitrile, N,N-dimethylformamide or water.
7. A process according to claim 1, wherein the base is potassium carbonate.
8. A process according to claim 1, wherein the molar ratio of 4-chloro-2-aminophenol to ethyl chloroformate ranges from 1.2 to 1.4.
9. A process according to claim 1, wherein the reaction is carried out at a temperature of 55-60° C.
US15/214,499 2015-07-23 2016-07-20 Process for the synthesis of chlorzoxazone Expired - Fee Related US9567308B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102015000037594 2015-07-23
ITUB2015A002422A ITUB20152422A1 (en) 2015-07-23 2015-07-23 PROCESS FOR CHLORZOXAZONE SYNTHESIS

Publications (2)

Publication Number Publication Date
US20170022172A1 true US20170022172A1 (en) 2017-01-26
US9567308B1 US9567308B1 (en) 2017-02-14

Family

ID=54364513

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/214,499 Expired - Fee Related US9567308B1 (en) 2015-07-23 2016-07-20 Process for the synthesis of chlorzoxazone

Country Status (2)

Country Link
US (1) US9567308B1 (en)
IT (1) ITUB20152422A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113816920A (en) * 2020-06-18 2021-12-21 鲁南制药集团股份有限公司 Synthetic method of chlorzoxazone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2895877A (en) * 1956-07-30 1959-07-21 Mcneilab Inc Composition and method for relieving spasticity
BR7204020D0 (en) * 1971-06-24 1973-11-01 Hoechst Ag PROCESS FOR OBTAINING BENZOXAZOLONES- (2) AND BENZOTIAZOLONES- (2)
FR2521994A1 (en) * 1982-02-23 1983-08-26 Ugine Kuhlmann PROCESS FOR THE PREPARATION OF BENZOXAZOLONE-2 AND DERIVATIVES FROM ORTHONITROPHENOLS AND CARBON MONOXIDE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113816920A (en) * 2020-06-18 2021-12-21 鲁南制药集团股份有限公司 Synthetic method of chlorzoxazone

Also Published As

Publication number Publication date
ITUB20152422A1 (en) 2017-01-23
US9567308B1 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
HUE029528T2 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof
US9567308B1 (en) Process for the synthesis of chlorzoxazone
US5616799A (en) Process for the preparation of glycoloylanilides
KR0178542B1 (en) Salt of dithiocarbamic acid, production thereof, and production of isothiocyanate from said salt
CN113242856A (en) N-nitrosaccharin
NO317648B1 (en) Process for Preparation of HIV Protease Inhibitors
JP4639382B2 (en) Novel N-sulfenylbenzotriazole compound and method for producing the same
EP1348693B1 (en) A process for the preparation of diazonaphthoquinonesulfonylchlorides using diphosgene and triphosgene
US6559291B1 (en) Process for the preparation of diazonaphthoquinonesulfonylchlorides using diphosgene and triphosgene
JP2818476B2 (en) Method for producing chlorinated nicotinaldehyde
CN104710324A (en) Lacosamide synthesis method
RU2754708C1 (en) Method for obtaining gliclazide
US20090286996A1 (en) Process for the preparation of zileuton
EP0413832A1 (en) Oxazolidinedione derivatives and production thereof
Takechi et al. Synthesis of 3-aminoflavones from 3-hydroxyflavones via 3-tosyloxy-or 3-mesyloxyflavones
EP3710445B1 (en) Process for the preparation of raltegravir
WO2019008595A1 (en) Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof
US7288678B2 (en) Process for preparing terbinafine by using platinum as catalyst
EP0200429A2 (en) Process for preparing methylcarbamate insecticides
RU2315747C2 (en) Method for production of acetylene compound
EP0357192B1 (en) Process for preparing substituted guanylthioureas
EP1832578B1 (en) Method for producing thiocarbamate derivative
JP7096078B2 (en) A method for producing a semicarbazide compound and a method for producing a triazolidinedione compound.
US4603211A (en) Process for the preparation of 1,2-benzoxathiine derivatives
JPH06228149A (en) Novel pentacyclic heterocyclic compound, production intermediate and their production

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROCOS S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOGOGNA, LUIGI;CICIONE, LAVINIA;BAROZZA, ALESSANDRO;AND OTHERS;REEL/FRAME:039195/0159

Effective date: 20160526

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210214